A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
Seung-Hwan LeeIra GantzElizabeth RoundMelanie LathamEdward A O'NeillPaulette CeesayShailaja SuryawanshiKeith D KaufmanSamuel S EngelEseng LaiPublished in: BMC endocrine disorders (2017)
ClinicalTrials.gov: NCT01704261 , EudraCT Number: 2012-002612-10. Trial Registration Date: October 8, 2012.